Polynovo Limited (CALZF)
OTHER OTC:CALZF
Want to see CALZF full AI Analyst Report?
CALZF Stock Chart & Stats
$0.73
-$0.78(-42.86%)
At close: 4:00 PM EST
$0.73
-$0.78(-42.86%)
Day’s Range― - ―
52-Week Range$0.55 - $1.20
Previous CloseN/A
Volume1.00K
Average Volume (3M)1.06K
Market Cap
$506.22M
Enterprise Value$700.28M
Total Cash (Recent Filing)$29.26M
Total Debt (Recent Filing)$31.74M
Price to Earnings (P/E)70799.0
Beta1.92
Next Earnings
Aug 21, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding690,843,000
10 Day Avg. Volume2,300
30 Day Avg. Volume1,056
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)9.95
Price to Sales (P/S)6.51
P/FCF Ratio-76.87
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue5.08
Enterprise Value/Gross Profit15.71
Enterprise Value/Ebitda98.34
Forecast
1Y Price Target
$1.21Price Target Upside65.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$109.18M
Bulls Say, Bears Say
Bulls Say
Durable Revenue Growth And US Commercial ScaleDouble‑digit group growth and strong U.S. expansion (25%+ growth, >800 accounts) combined with rapid MTX adoption (+193%) indicate durable commercial traction. A broadening hospital account base and product adoption create recurring consumable demand that supports sustainable revenue scaling across markets.
Very High Gross Margins And Improving ProfitabilityExceptionally high gross margins and materially improved adjusted EBITDA reflect strong unit economics from the NovoSorb platform. High gross margins provide a lasting buffer to absorb SG&A and R&D investment, supporting reinvestment and margin sustainability as volumes scale internationally.
Scaled Manufacturing And Regulatory Pathway (PMA/BARDA)A validated facility with ~5x prior capacity plus an on‑label PMA process with BARDA materially improves supply capability and regulatory credibility. This structural lift reduces production bottlenecks and supports larger U.S. programs and commercial scale following regulatory approvals.
Bears Say
Weak Cash Conversion And Negative FCF GrowthDespite improving operating cash flow, weak free cash flow growth and a low OCF-to-net-income ratio indicate limited cash conversion. Persistently weak conversion can constrain self‑funded expansion, increase reliance on external capital and heighten sensitivity to execution when scaling operations.
Outpatient Reimbursement And Regulatory UncertaintyUncertainty around CMS outpatient reimbursement and the likely need for an RCT mean outpatient adoption and revenue are not guaranteed. This structural reimbursement risk can delay addressable market expansion, raise market access costs and make outpatient upside conditional on successful trial outcomes.
Lumpy Burn Demand And Slower Market DevelopmentExposure to irregular large burn cases, seasonality and complex tender processes (notably in India) creates structural demand volatility. Lumpy volumes reduce revenue visibility, complicate forecasting and slow payback on commercial investments, making steady growth harder to predict.
Polynovo News
CALZF FAQ
What was Polynovo Limited’s price range in the past 12 months?
Polynovo Limited lowest stock price was $0.55 and its highest was $1.20 in the past 12 months.
What is Polynovo Limited’s market cap?
Polynovo Limited’s market cap is $506.22M.
When is Polynovo Limited’s upcoming earnings report date?
Polynovo Limited’s upcoming earnings report date is Aug 21, 2026 which is in 102 days.
How were Polynovo Limited’s earnings last quarter?
Polynovo Limited released its earnings results on Feb 20, 2026. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.004 by -$0.004.
Is Polynovo Limited overvalued?
According to Wall Street analysts Polynovo Limited’s price is currently Undervalued.
Does Polynovo Limited pay dividends?
Polynovo Limited does not currently pay dividends.
What is Polynovo Limited’s EPS estimate?
Polynovo Limited’s EPS estimate is <0.01.
How many shares outstanding does Polynovo Limited have?
Polynovo Limited has 690,843,000 shares outstanding.
What happened to Polynovo Limited’s price movement after its last earnings report?
Polynovo Limited reported an EPS of $0 in its last earnings report, missing expectations of $0.004. Following the earnings report the stock price went down -3.116%.
Which hedge fund is a major shareholder of Polynovo Limited?
Currently, no hedge funds are holding shares in CALZF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Polynovo Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.21 (65.20% Upside)
$1.21 (65.20% Upside)
Blogger Sentiment
Bullish
CALZF Sentiment 96%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $187.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.28%
12-Months-Change
Fundamentals
Return on Equity
11.87%
Trailing 12-Months
Asset Growth
17.90%
Trailing 12-Months
Company Description
Polynovo Limited
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
CALZF Company Deck
CALZF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and commercial picture: double‑digit revenue growth across major regions (group +26%, U.S. +25.3%, RoW +28.3%), rapid MTX adoption (~+193%), improved cash flow (+$9.0M) and a strong clinical evidence base (348 studies). Key strategic catalysts (PMA submission, SynPath outpatient pathway, expanded manufacturing capacity, recruitment of a Chief Scientific Officer) provide clear upside. Short‑term headwinds include a timing‑related manufacturing variance (~$3.6–3.7M) from planned slowdowns, an R&D lab fire asset write‑off (insured), FX translation losses, and reimbursement/regulatory uncertainty for outpatient CMS coverage which may require an RCT. Management frames several negatives as one‑offs or timing issues and expects margin and free cash flow improvement in H2. Overall, highlights materially outweigh the lowlights.View all CALZF earnings summariesCALZF Stock 12 Month Forecast
Average Price Target
$1.21
▲(65.20% Upside)
Technical Analysis
Nova Eye Medical
―
Cochlear
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―
Ownership Overview
3.36% Insiders
2.71% Mutual Funds
― Other Institutional Investors
90.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---